Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results

same period in 2010 of $10.1 million, or $0.54 per share.  The increase in net loss per share for the three months ended March 31, 2011 compared to the same period in 2010 was a result of the increase in net loss, partially offset by an increase in weighted-average shares outstanding in 2011 as a result of our April 2010 and February 2011 public offerings of common stock.ARDEA BIOSCIENCES, INC.Condensed Consolidated Statements of Operations(in thousands, except per share amounts)Three Months Ended

March 31,

(Unaudited)20112010Revenues: License fees



2,426 Sponsored research90— Reimbursable research and development costs603847Total revenues1,7703,273Operating expenses: Research and development12,71510,251 General and administrative4,2492,926Total operating expenses16,96413,177Loss from operations(15,194)(9,904)Other income (expense): Interest income10769 Interest expense(134)(261) Other income, net313Total other income (expense)(24)(179)Net loss



(10,083)Basic and diluted net loss per share



(0.54)Shares used in computing basic and diluted net loss per share 25,78218,559Condensed Consolidated Balance Sheet Data(in thousands)March 31,


(Unaudited)December 31,

2010Cash, cash equivalents and short-term investments



80,612Total assets



100,454Total stockholders' equity



77,123About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue t

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
3. Ardea Biosciences Prices Public Offering of Common Stock
4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Post Your Comments:
(Date:7/28/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... synthetic biology covers the designing and engineering of completely ... the redesigning of natural biological systems that provide improved ... form of extreme genetic engineering because it not only ...
(Date:7/28/2014)... , July 28, 2014  David Hardison, Ph.D., ... by Deloitte , has been elected chairman of ... Consortium, a non-profit working to establish common protocols ... as it relates to electronic health records. ... mission of collaborating with organizations across the research ...
(Date:7/28/2014)... MO (PRWEB) July 28, 2014 ... and services that bring the power of genomics to ... inaugural Appistry Pipeline Challenge . , Two ... president of the National Center for Genome Resources, and ... Hospitals and Clinics of Kansas City. Rounding out the ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2
... May 27 Informed Medical Communications,(IMC), a leading ... today announced the appointment of Bert,Marchio to the ... ), Marchio brings to ... financial,leadership positions in both the public and private ...
... ATLANTA, May 27 CryoLife, Inc. (NYSE: CRY ... today,that it is scheduled to participate in the FBR ... at the Grand Hyatt Hotel,in New York City., ... CryoLife,Inc., will present at 12:50 p.m. Eastern Time., ...
... Expands its Leading Position in Next-Generation Sequencing, ... febit,today announced the receipt of US patent #7320862 ... and RNA., This method forms the basis ... of next-generation sequencers in genomic research. Further,investigation of ...
Cached Biology Technology:Informed Medical Communications Appoints New Chief Financial Officer 2CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference 2febit Receives U.S. Patent for Microfluidic Extraction Method 2
(Date:7/28/2014)... the Earth that are high priorities for conservation in ... vulnerable, as it has the lowest fraction of its ... in ,refugia, areas of biological diversity that support ... during times of great environmental change. The refugia that ... Scotland. , The biggest refugia are in the ...
(Date:7/28/2014)... & Behavior Research Foundation today announced the winners ... exceptional clinical and basic research by young scientists ... Grants. The grants enable early career scientists to ... for the prevention, early detection, treatment, and cure ... people. , Six young scientistswinners of the Klerman ...
(Date:7/28/2014)... many of these due to genetic factors. This is ... which reduce an individual,s ability to reproduce, to disappear ... Science that recently appeared in Nature Communications ... it explain the high rates of male fertility problems, ... of genetic diseases and their treatment. , Various ...
Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Mutations from Venus, mutations from Mars 2
... has found that you are more likely to perform well ... your instincts. The research, published online today in the journal ... are more reliable than decisions taken using higher-level cognitive processes. ... out on a screen covered in over 650 identical symbols, ...
... one type of stimuli, our sense of smell works double ... we smell, according to University of Pennsylvania School of Medicine ... This finding, plus the fact that both types of stimuli ... brain perceives what we smell, explains why we sniff to ...
... and sea levels in the centuries to come? Are we ... the oceans on the rise? Can aquaculture be environmentally sustainable? ... of coastal fisheries? , Most importantly, what can governments, industry ... news media are invited to join leading international researchers and ...
Cached Biology News:Trusting your instincts leads you to the right answer 2Trusting your instincts leads you to the right answer 3Penn study on olfactory nerve cells shows why we smell better when we sniff 2Are we killing the world's oceans? 2